Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

Imara, the US-based hemoglobinopathy drug developer backed by pharmaceutical firms Lundbeck and Pfizer, went public yesterday in a $75.2m initial public offering on the Nasdaq Global Select Market. The offering consisted of 4.7 million shares priced at $16.00 each, increasing the number slightly from 4.45 million. The company floated at the low end of the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.